Skip to content
Science

Testosterone After 60: Safe and Effective Optimization Strategies

11 min read
#testosterone#aging#men over 60#TRT#hormone optimization#longevity

Testosterone after 60 is a different conversation than it is for younger men. The goals shift from performance toward preserving muscle, bone, function and quality of life, and doing so safely in the context of age-related health conditions. The evidence base has improved significantly in recent years, particularly with the 2023 TRAVERSE trial, which reshaped the discussion of cardiovascular safety, and its later fracture analysis, which added a new caution. This guide is educational information, not medical advice.

Key takeaways

In healthy non-obese men aged 60 to 69, median total testosterone was about 477 ng/dL (middle 90 percent: roughly 254 to 839 ng/dL), similar to men in their 50s.[1]

In TRAVERSE (5,246 men aged 45 to 80), major cardiovascular events occurred in 7.0 percent on testosterone and 7.3 percent on placebo, but atrial fibrillation, acute kidney injury and pulmonary embolism were more common with testosterone.[2]

In the TRAVERSE fracture substudy, clinical fractures occurred in 3.50 percent on testosterone and 2.46 percent on placebo (hazard ratio 1.43).[3]

A meta-analysis found resistance training did not significantly change basal testosterone in men aged 60 and older.[4] WHO still recommends multicomponent activity including strength and balance on 3 or more days a week for older adults.[5]

7.0% vs 7.3%
Major cardiovascular events, testosterone vs placebo (TRAVERSE)
5,246 men aged 45 to 80, mean follow-up 33 months, hazard ratio 0.96

Normal Aging vs. Pathological Hypogonadism

An essential distinction for men over 60 is the difference between the gradual decline in testosterone that accompanies aging and true late-onset hypogonadism, a condition that may warrant treatment. Treating a normal variant as a disease can lead to unnecessary medication, while dismissing a genuine deficiency as “getting old” can cost quality of life.

In harmonized reference data, the median total testosterone of non-obese men is about 477 ng/dL at ages 60 to 69, nearly identical to ages 50 to 59 (477), with the 5th to 95th percentile spanning about 254 to 839 ng/dL. Among all men aged 60 to 69, including those with obesity, the median is about 446 ng/dL (5th to 95th percentile roughly 221 to 812). The upper end of the range barely changes with age, while the lower end drops.[1]

What separates normal aging from a medical problem is the combination of symptoms and consistently low results. In a survey of 3,369 European men aged 40 to 79, only the three sexual symptoms (poor morning erections, low sexual desire and erectile dysfunction) showed a syndromic relationship with lower testosterone, while fatigue and low mood were related but far less specific. The authors defined late-onset hypogonadism as at least three sexual symptoms together with total testosterone below 11 nmol/L (about 320 ng/dL) and free testosterone below 220 pmol/L.[6] The Endocrine Society advises diagnosing hypogonadism only in men with symptoms and unequivocally low fasting morning total testosterone confirmed on repeat testing.[7]

Many conditions common after 60 can lower testosterone on their own, including obesity and chronic illness, and the guideline recommends evaluating the cause in men found to be deficient.[7] As our testosterone after 50 guide details, the first step is identifying reversible contributors.

The TRAVERSE Trial: What We Now Know About Safety

For years, the safety of testosterone therapy in older men was clouded by a 2010 trial in men aged 65 and older with mobility limitations. It was stopped early by its safety board after 209 men were enrolled because of a higher rate of cardiovascular adverse events with testosterone gel (23 men versus 5 on placebo). The authors themselves cautioned that the small size and unique population prevented broader conclusions.[8]

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was designed to answer the question. It randomized 5,246 men aged 45 to 80 with symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and preexisting or a high risk of cardiovascular disease to testosterone gel or placebo. Mean follow-up was 33 months. A primary event (cardiovascular death, nonfatal heart attack or nonfatal stroke) occurred in 182 men (7.0 percent) on testosterone and 190 (7.3 percent) on placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17), meeting the noninferiority criterion.[2]

TRAVERSE was not entirely reassuring. A higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism was observed in the testosterone group.[2] A later analysis of the trial found that clinical fractures occurred in 91 men (3.50 percent) on testosterone and 64 (2.46 percent) on placebo (hazard ratio 1.43, 95% CI 1.04 to 1.97), so testosterone did not lower fracture incidence and the rate was numerically higher.[3] The trial population was also specific: men with symptomatic, confirmed low testosterone and cardiovascular risk, followed for under three years. It does not establish long-term safety, and it does not apply to men with normal testosterone.

TRAVERSE in Context

TRAVERSE was a large randomized, placebo-controlled trial designed to test cardiovascular safety. Its result is cardiovascular reassurance for the specific population studied, not blanket safety. Regular monitoring with a doctor remains essential during therapy. See our article on testosterone and cardiovascular health.

Prostate Safety: Updated Evidence

The historical fear that testosterone therapy “feeds” prostate cancer came from mid-20th century observations that removing testosterone shrinks advanced prostate cancer. A review of four larger randomized trials, including TRAVERSE, found that, among men with hypogonadism who were carefully screened to exclude those at high risk of prostate cancer, the incidence of high-grade or any prostate cancer, urinary retention, prostate procedures and new urinary-symptom treatment was low and did not differ between testosterone and placebo. PSA rose more with testosterone than placebo in the first year. The authors concluded that treatment of screened men is associated with a low risk of adverse prostate events and recommend a baseline evaluation of prostate cancer risk plus a standardized monitoring plan.[9]

The Endocrine Society still recommends against starting testosterone therapy in men with breast or prostate cancer, a palpable prostate nodule, elevated PSA (above 4 ng/mL, or above 3 ng/mL in men at higher risk) without further urological evaluation, or severe lower urinary tract symptoms.[7] For more, see testosterone and prostate health.

Exercise for Men Over 60: Realistic Expectations

A systematic review and meta-analysis of 22 studies in men aged 60 and older found that resistance training did not significantly influence basal testosterone, while endurance and interval training showed small but significant increases. The authors described the data as encouraging but limited.[4] So exercise is best thought of as a way to preserve strength and function, with any testosterone change as a possible bonus.

On function, the WHO 2020 guidelines recommend that older adults do varied multicomponent physical activity that emphasizes functional balance and strength training at moderate or greater intensity on 3 or more days a week to enhance functional capacity and prevent falls. The guidelines also say older adults should be as active as their functional ability allows.[5] If you have heart disease, joint problems or have been inactive, talk to a doctor or qualified trainer about how to start and progress. Our guide to the best exercises for testosterone covers movement choices in more detail.

Recovery Matters

Recovery capacity changes with age. Build up gradually, allow rest between hard sessions, and reduce volume if joint pain or unusual fatigue develops. Consistency over months matters more than intensity on any single day.

Bone Density and Testosterone

Testosterone is involved in bone metabolism, and the evidence for treatment is mixed. In a one-year placebo-controlled trial in 211 men aged 65 and older with low testosterone, testosterone gel increased spine trabecular volumetric bone density by 7.5 percent versus 0.8 percent on placebo (treatment effect 6.8 percent) and increased estimated bone strength, with the authors noting that a larger, longer trial was needed to determine effects on fractures.[10] That larger trial then reported more clinical fractures with testosterone (3.50 versus 2.46 percent), described above.[3] Better bone density on a scan has not been shown to mean fewer fractures in this setting. If you are concerned about bone health, ask your doctor about bone density testing, calcium and vitamin D status, and fall prevention.

Cognitive Function and Brain Health

Observational studies have linked low testosterone with cognitive decline, but treatment trials have not shown a benefit. In a placebo-controlled trial in 493 older men (mean age 72) with low testosterone and age-associated memory impairment, one year of testosterone treatment was not associated with improved memory or other cognitive functions (delayed paragraph recall, visual memory, executive function or spatial ability).[11] Brain health in aging is better supported by exercise, sleep, social engagement and management of cardiovascular risk factors. Testosterone is not a cognitive enhancer.

Medications Matter

Men over 60 are more likely to take medications that affect, or are affected by, testosterone. The clearest example is chronic opioid use, which a 2025 review describes as a common but underappreciated cause of androgen deficiency in men; opioids suppress the gonadal axis mainly by inhibiting GnRH synthesis and secretion.[12] If you take opioids for chronic pain and have symptoms, discuss this with your prescriber. More generally, tell your doctor and pharmacist about every medication and supplement you use before any hormone therapy is considered, since testosterone therapy requires monitoring and can interact with other treatments.

When TRT Is Appropriate After 60

The Endocrine Society recommends testosterone therapy for men with symptomatic testosterone deficiency after discussing the potential benefits and risks and the monitoring involved, and it lists conditions in which therapy should not be started.[7] In summary, doctors generally look for:

✓ What Doctors Look For

  • •Symptoms consistent with deficiency
  • •Consistently low fasting morning total testosterone, confirmed on repeat testing
  • •Causes evaluated (weight, sleep apnea, medications, other conditions)
  • •No contraindications (prostate cancer, elevated hematocrit, untreated severe sleep apnea, recent heart attack or stroke, near-term fertility plans)
  • •Willingness to follow a monitoring plan

✗ Poor Reasons to Start

  • •Treating normal age-related change without a confirmed deficiency
  • •Starting therapy on a single test result
  • •Ignoring reversible causes such as obesity, sleep apnea or medications
  • •Seeking testosterone primarily for muscle building
  • •Skipping monitoring of hematocrit, PSA and symptoms

When therapy is started, the guideline suggests aiming for testosterone concentrations in the mid-normal range with a standardized monitoring plan covering symptoms, adverse effects, testosterone and hematocrit, and prostate cancer risk.[7] This decision should be made with an endocrinologist or urologist. For a comparison of approaches, see our TRT vs. natural optimization guide.

Lifestyle Strategies Worth Discussing

Whether or not a man uses TRT, lifestyle foundations matter for health in their own right. No lifestyle change is guaranteed to raise testosterone, and the best-supported lever is body weight in men with obesity, where weight loss is associated with higher testosterone (see our guide to body fat and testosterone). Sleep is another: untreated sleep apnea is worth treating for its own sake, and read our guide on sleep and testosterone. For nutrition, adequate protein and a varied diet are sensible, but specific targets (and any supplements) are best set with your doctor, particularly if you have kidney disease or take medications. As covered in our testosterone after 40 guide, the same foundations apply across decades.

Practical Takeaways

A Sensible Checklist for Men Over 60

See your doctor about symptoms

Persistent sexual symptoms, unexplained fatigue or low mood deserve a proper evaluation. Ask whether fasting morning testing, repeated, is appropriate for you.

Look for reversible causes

Excess weight, sleep apnea, medications such as opioids, and other health conditions can all affect testosterone. Treating them matters regardless of hormones.

Stay active

WHO recommends varied multicomponent activity with strength and balance work on 3 or more days a week for older adults. Check with a doctor if you have heart or joint problems.

Eat and sleep for health

A varied diet, adequate protein and consistent sleep support overall health. Ask a doctor before taking supplements.

Discuss TRT only with a specialist

If symptoms and confirmed low levels persist, talk to an endocrinologist or urologist about benefits, risks and monitoring, including heart, prostate, hematocrit and bone considerations.

How Thrive Helps

Thrive is a habit-tracking app that helps you stay consistent with everyday routines around sleep, activity, nutrition and stress. It is a wellness app, not a medical device, and it does not diagnose or treat any condition or replace medical advice. Try Thrive free and bring your habit data to your next conversation with your doctor.

References

  1. Travison TG, Vesper HW, Orwoll E, et al.. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab. 2017. doi.org/10.1210/jc.2016-2935
  2. Lincoff AM, Bhasin S, Flevaris P, et al.. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023. doi.org/10.1056/NEJMoa2215025
  3. Snyder PJ, Bauer DC, Ellenberg SS, et al.. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024. doi.org/10.1056/NEJMoa2308836
  4. Hayes LD, Elliott BT. Short-term exercise training inconsistently influences basal testosterone in older men: a systematic review and meta-analysis. Front Physiol. 2018. doi.org/10.3389/fphys.2018.01878
  5. Bull FC, Al-Ansari SS, Biddle S, et al.. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020. doi.org/10.1136/bjsports-2020-102955
  6. Wu FC, Tajar A, Beynon JM, et al.. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010. doi.org/10.1056/NEJMoa0911101
  7. Bhasin S, Brito JP, Cunningham GR, et al.. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. doi.org/10.1210/jc.2018-00229
  8. Basaria S, Coviello AD, Travison TG, et al.. Adverse events associated with testosterone administration. N Engl J Med. 2010. doi.org/10.1056/NEJMoa1000485
  9. Bhasin S, Thompson IM. Prostate risk and monitoring during testosterone replacement therapy. J Clin Endocrinol Metab. 2024. doi.org/10.1210/clinem/dgae334
  10. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al.. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017. doi.org/10.1001/jamainternmed.2016.9539
  11. Resnick SM, Matsumoto AM, Stephens-Shields AJ, et al.. Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. JAMA. 2017. doi.org/10.1001/jama.2016.21044
  12. Kafel H, Braga-Basaria M, Basaria S. Opioid-induced androgen deficiency in men: prevalence, pathophysiology, and efficacy of testosterone therapy. Andrology. 2025. doi.org/10.1111/andr.70013

Frequently Asked Questions

In the TRAVERSE trial of 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease, major cardiovascular events occurred in 7.0 percent of men on testosterone gel and 7.3 percent on placebo over a mean of 33 months, meeting the noninferiority criterion. However, atrial fibrillation, acute kidney injury and pulmonary embolism were more common with testosterone, and a fracture substudy found clinical fractures in 3.50 percent versus 2.46 percent. Testosterone therapy is a medical decision that requires monitoring by a qualified doctor.
It varies widely. In harmonized data from four cohorts, healthy non-obese men aged 60 to 69 had a median total testosterone of about 477 ng/dL, similar to men in their 50s, with the middle 90 percent of values between roughly 254 and 839 ng/dL. Among all men aged 60 to 69, including those with obesity, the median was about 446 ng/dL. Longitudinal studies show a gradual average decline, and body weight and health conditions are associated with lower levels.
Evidence is limited. A meta-analysis of 22 studies in men aged 60 and older found that resistance training did not significantly change basal testosterone, though aerobic and interval training showed small increases. WHO recommends varied multicomponent physical activity emphasizing balance and strength on 3 or more days a week for older adults to enhance functional capacity and prevent falls, regardless of any hormone effect. Talk to a doctor before starting a new exercise program or if you have symptoms of low testosterone.

Ready to optimize?

Turn evidence into action. Download THRIVE Male Health and start building science-backed habits today.

Download Thrive